Clinicians and researchers belonging to two oncology networks, including one devoted to paraneoplastic syndromes, have studied neurological complications arising during the use of a new class of drugs, immune checkpoint inhibitors:
- 147 patients were included in the study, reflecting the significant frequency of the phenomenon;
- complications of the peripheral nervous system were more frequent than those of the central nervous system, the combination of the two being much rarer;
- the presence of associated myositis or neuromuscular junction damage, as well as the patient’s relatively young age, would appear to be factors with a better prognosis.
